Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

KALV KalVista Pharmaceuticals

14.510
+0.510+3.64%
Close 09/30 16:00 ET
14.5100.0000.00%
Post Mkt Price 09/30 16:02 ET
High
14.990
Open
14.040
Turnover
1.20M
Low
14.040
Pre Close
14.000
Volume
81.95K
Market Cap
356.98M
P/E(TTM)
Loss
52wk High
18.530
Shares
24.60M
P/E(Static)
Loss
52wk Low
8.000
Float Cap
204.91M
Bid/Ask %
-33.33%
Historical High
129.108
Shs Float
14.12M
Volume Ratio
0.71
Historical Low
5.480
Dividend TTM
--
Div Yield TTM
--
P/B
2.17
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.58%
Amplitude
6.79%
Avg Price
14.618
Lot Size
1
Float Cap
204.91M
Bid/Ask %
-33.33%
Historical High
129.108
Shs Float
14.12M
Volume Ratio
0.71
Historical Low
5.480
Dividend TTM
--
P/B
2.17
Dividend LFY
--
Turnover Ratio
0.58%
Amplitude
6.79%
Avg Price
14.618
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.
CEO: Mr. Thomas Andrew Crockett
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...